The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety

被引:165
作者
Copeland, Robert A. [1 ]
机构
[1] Epizyme Inc, Cambridge, MA 02139 USA
关键词
drug-target interactions; efficacy; koff; residence time; safety; RECEPTOR ANTAGONISTS; BINDING-KINETICS; INHIBITION; PROTEASE; OPTIMIZATION; DISSOCIATION; PROTECTION; DISCOVERY; BEHAVIOR; LIGAND;
D O I
10.1517/17460441003677725
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
The extent and duration of pharmacological action is determined by the lifetime of drug occupancy on a molecular target. This lifetime is defined by dynamic processes that control the rates of drug association and dissociation from the target. Recently, the term residence time has been coined to describe experimental measurements that can be related to the lifetime of the binary drug-target complex, and this in turn to durable, pharmacodynamic activity. The residence time concept and its impact on drug optimization are reviewed here. Examples are provided that demonstrate how a long residence time can improve drug efficacy in vivo. Additionally, optimization of drug-target residence time can help to mitigate off-target mediated toxicity, hence, improving drug safety and tolerability. Recent applications of the residence time concept to both drug discovery and development are also presented.
引用
收藏
页码:305 / 310
页数:6
相关论文
共 30 条
[1]
The role of dynamic conformational ensembles in biomolecular recognition [J].
Boehr, David D. ;
Nussinov, Ruth ;
Wright, Peter E. .
NATURE CHEMICAL BIOLOGY, 2009, 5 (11) :789-796
[2]
Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I):: In vitro effects on platelets [J].
Bryant, Judi ;
Post, Joseph M. ;
Alexander, Serene ;
Wang, Yi-Xin ;
Kent, Lorraine ;
Schirm, Sabine ;
Tseng, Jih-Lie ;
Subramanyam, Babu ;
Buckman, Brad ;
Islam, Imadul ;
Yuan, Shendong ;
Sullivan, Mark E. ;
Snider, Mike ;
Morser, John .
THROMBOSIS RESEARCH, 2008, 122 (04) :523-532
[3]
Optical biosensors in drug discovery [J].
Cooper, MA .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (07) :515-528
[4]
Copeland R., 2005, EVALUATION ENZYME IN, V1st
[5]
Copeland RA, 2000, ENZYMES PRACTICAL IN
[6]
Opinion - Drug-target residence time and its implications for lead optimization [J].
Copeland, Robert A. ;
Pompliano, David L. ;
Meek, Thomas D. .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (09) :730-739
[7]
Integrating surface plasmon resonance biosensor-based interaction kinetic analyses into the lead discovery and optimization process [J].
Danielson, U. Helena .
FUTURE MEDICINAL CHEMISTRY, 2009, 1 (08) :1399-1414
[8]
Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier [J].
Dierynck, Inge ;
De Wit, Mieke ;
Gustin, Emmanuel ;
Keuleers, Inge ;
Vandersmissen, Johan ;
Hallenberger, Sabine ;
Hertogs, Kurt .
JOURNAL OF VIROLOGY, 2007, 81 (24) :13845-13851
[9]
Ehrlich P, 1913, LANCET, V2, P445
[10]
Fischer E., 1894, BER DTSCH CHEM GES, V27, P2985, DOI [10.1002/cber.18940270364, DOI 10.1002/CBER.18940270364]